ESR1 and metastatic neoplasm: These studies have collectively shown that ESR1 mutations present rarely in primary treatment-naive ER+ breast cancer, whereas they are highly prevalent in metastatic tumors, suggesting that these mutations may potentially arise from rare clones of primary tumors through clonal selection against endocrine therapy (ET)10–13.